CY1110927T1 - Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων - Google Patents

Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων

Info

Publication number
CY1110927T1
CY1110927T1 CY20071101290T CY071101290T CY1110927T1 CY 1110927 T1 CY1110927 T1 CY 1110927T1 CY 20071101290 T CY20071101290 T CY 20071101290T CY 071101290 T CY071101290 T CY 071101290T CY 1110927 T1 CY1110927 T1 CY 1110927T1
Authority
CY
Cyprus
Prior art keywords
rantes
amino
competent
chemicals
relates
Prior art date
Application number
CY20071101290T
Other languages
English (en)
Inventor
Paul W Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110927(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1110927T1 publication Critical patent/CY1110927T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με αμινο-καταληκτικώς διακλαδισμένες RANTES, στερούμενες των NH2-καταληκτικών αμινοξέων που αντιστοιχούν στα αμινοξικά κατάλοιπα 1, 1-2, 1-3 ή 1-4 της φυσικής RANTES και οι οποίες διαθέτουν ανταγωνιστική της χημοκίνης δραστηριότητα. Σχετίζεται επίσης με τις αλληλουχίες του cDNA που τις κωδικεύει, με τη χρήση τους στη θεραπεία και/ή διάγνωση των νόσων εκείνων στις οποίες απαιτείται μια ανταγωνιστική των επιδράσεων της χημοκίνης δραστηριότητα, καθώς και με τα φαρμακευτικά σκευάσματα που τις περιέχουν.
CY20071101290T 1997-09-29 2007-10-08 Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων CY1110927T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP04007579A EP1439231B1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated rantes as chemokine antagonists

Publications (1)

Publication Number Publication Date
CY1110927T1 true CY1110927T1 (el) 2015-06-10

Family

ID=8227408

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101290T CY1110927T1 (el) 1997-09-29 2007-10-08 Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων

Country Status (29)

Country Link
US (5) US6977071B2 (el)
EP (6) EP0906954A1 (el)
JP (2) JP4230659B2 (el)
KR (2) KR100560275B1 (el)
CN (3) CN1145693C (el)
AR (2) AR013529A1 (el)
AT (3) ATE263242T1 (el)
AU (2) AU750606B2 (el)
BG (2) BG64757B1 (el)
BR (2) BR9812565A (el)
CA (2) CA2304827A1 (el)
CY (1) CY1110927T1 (el)
CZ (2) CZ299478B6 (el)
DE (3) DE69823218T2 (el)
DK (3) DK1019507T3 (el)
EA (2) EA003940B1 (el)
EE (2) EE200000152A (el)
ES (3) ES2215324T3 (el)
HK (3) HK1062637A1 (el)
HU (2) HU226414B1 (el)
IL (2) IL135351A (el)
NO (2) NO20001584L (el)
NZ (3) NZ516027A (el)
PL (2) PL197569B1 (el)
PT (3) PT1021541E (el)
SK (2) SK286439B6 (el)
UA (2) UA73081C2 (el)
WO (2) WO1999016877A1 (el)
ZA (2) ZA988676B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6534626B1 (en) 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU1259501A (en) * 1999-10-25 2001-05-08 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
ATE421974T1 (de) 2001-12-17 2009-02-15 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
CN101802211B (zh) 2007-08-02 2014-10-01 诺维莫尼公司 抗正常t细胞表达和分泌活化调节因子(rantes)抗体及其使用方法
US20130053257A1 (en) * 2010-02-08 2013-02-28 Paul E. Oran RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity
US9296803B2 (en) 2010-03-11 2016-03-29 Health Research, Inc. Methods and compositions containing Fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
US20210205412A1 (en) 2018-05-28 2021-07-08 Université De Genève Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US6159711A (en) * 1994-12-08 2000-12-12 Glaxo Group Limited DNA encoding rantes peptide fragments and methods of treatment with the fragments
AU1532697A (en) * 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
JP2000508527A (ja) * 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
EP1019507A1 (en) 2000-07-19
WO1999016876A1 (en) 1999-04-08
NZ503234A (en) 2002-06-28
EP1021541A1 (en) 2000-07-26
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
CZ20001146A3 (cs) 2000-09-13
IL135352A (en) 2006-08-20
EP1021541B1 (en) 2004-04-14
US7326411B2 (en) 2008-02-05
AU750606B2 (en) 2002-07-25
EP1439231A2 (en) 2004-07-21
ES2218860T3 (es) 2004-11-16
ES2287601T3 (es) 2007-12-16
JP2001518297A (ja) 2001-10-16
BR9812394A (pt) 2000-09-12
ATE264390T1 (de) 2004-04-15
UA73081C2 (en) 2005-06-15
AU750341B2 (en) 2002-07-18
ATE368742T1 (de) 2007-08-15
IL135351A (en) 2006-08-20
HK1062637A1 (en) 2004-11-19
EE200000152A (et) 2001-02-15
AU9747498A (en) 1999-04-23
AR013529A1 (es) 2000-12-27
BG104266A (en) 2000-11-30
PL339545A1 (en) 2000-12-18
ATE263242T1 (de) 2004-04-15
EA200000378A1 (ru) 2000-10-30
HK1032425A1 (en) 2001-07-20
US6905676B2 (en) 2005-06-14
US20030119148A1 (en) 2003-06-26
US20050220790A1 (en) 2005-10-06
JP4230659B2 (ja) 2009-02-25
NO20001584D0 (no) 2000-03-27
KR100542934B1 (ko) 2006-01-11
BG64757B1 (bg) 2006-02-28
NZ503235A (en) 2002-08-28
EP0905240A1 (en) 1999-03-31
US6977071B2 (en) 2005-12-20
UA73080C2 (en) 2005-06-15
HUP0003505A2 (hu) 2001-02-28
NO20001609L (no) 2000-03-28
HU226414B1 (en) 2008-11-28
DE69838188D1 (de) 2007-09-13
NZ516027A (en) 2003-05-30
HUP0003505A3 (en) 2005-11-28
EP0906954A1 (en) 1999-04-07
US7338653B2 (en) 2008-03-04
DE69823218T2 (de) 2004-08-26
PT1019507E (pt) 2004-06-30
WO1999016877A1 (en) 1999-04-08
NO20001584L (no) 2000-03-27
EA200000379A1 (ru) 2000-10-30
DE69838188T2 (de) 2007-11-22
EP1439231B1 (en) 2007-08-01
PL196427B1 (pl) 2008-01-31
HK1032426A1 (en) 2001-07-20
CA2304827A1 (en) 1999-04-08
CN1233415C (zh) 2005-12-28
CN1145693C (zh) 2004-04-14
DK1019507T3 (da) 2004-07-19
CN1271386A (zh) 2000-10-25
EP1439231A3 (en) 2004-12-22
DK1439231T3 (da) 2007-11-05
PL339559A1 (en) 2000-12-18
EP1019507B1 (en) 2004-03-31
DE69823218D1 (de) 2004-05-19
EA003942B1 (ru) 2003-10-30
CN1490049A (zh) 2004-04-21
KR100560275B1 (ko) 2006-03-10
SK286439B6 (sk) 2008-10-07
ES2215324T3 (es) 2004-10-01
ZA988675B (en) 1999-11-24
HU226468B1 (en) 2008-12-29
US20030124677A1 (en) 2003-07-03
US20050201977A1 (en) 2005-09-15
EP0905241A1 (en) 1999-03-31
CZ20001147A3 (cs) 2000-09-13
HUP0003563A2 (hu) 2001-02-28
EA003940B1 (ru) 2003-10-30
BG64679B1 (bg) 2005-11-30
HUP0003563A3 (en) 2005-11-28
CZ299479B6 (cs) 2008-08-06
KR20010024214A (ko) 2001-03-26
PT1021541E (pt) 2004-07-30
US20050164936A1 (en) 2005-07-28
EE200000151A (et) 2001-02-15
NO20001609D0 (no) 2000-03-28
JP4233214B2 (ja) 2009-03-04
PL197569B1 (pl) 2008-04-30
CN1271385A (zh) 2000-10-25
DE69822856D1 (de) 2004-05-06
AU9442098A (en) 1999-04-23
DE69822856T2 (de) 2004-08-19
CA2305017A1 (en) 1999-04-08
BR9812565A (pt) 2000-08-01
KR20010024213A (ko) 2001-03-26
SK4502000A3 (en) 2000-09-12
AR013528A1 (es) 2000-12-27
BG104267A (en) 2000-11-30
PT1439231E (pt) 2007-08-20
CZ299478B6 (cs) 2008-08-06
SK4512000A3 (en) 2000-09-12
JP2001518296A (ja) 2001-10-16
DK1021541T3 (da) 2004-08-02
CN1148447C (zh) 2004-05-05

Similar Documents

Publication Publication Date Title
CY1110927T1 (el) Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων
AR247590A1 (es) Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion
RU95115239A (ru) Аналог эритропоэтина
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ES2176284T3 (es) Amidas de peptidos inhibidoras del cancer de seres humanos.
DE68905387D1 (de) Aminosaeure-nahrungsmittelzusammensetzungen.
ATE218879T1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
DK0518608T3 (da) Smagsbevarende milde mundhygiejnepræparater
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
BR9808705A (pt) Agente amaciante de ácido e substância ativa para amaciar tecidos e composições para amaciar tecidos contendo a mesma
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
IT1212508B (it) Analoghi retro - invertiti dei penta - ed esapeptidi c - terminali della sostanza p. utili come vasodilatatori
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
HUP9900506A2 (hu) Protrombinszármazékok
ATE345139T1 (de) Karzinostatische wirkstoffe
ES2032465T3 (es) Variantes de la hirudina, su utilizacion y su preparacion.
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
DK482185D0 (da) Peptider, deres fremstilling og anvendelse som laegemidler
DE68920896D1 (de) N2-(1-Carboxy-3-phenylpropyl)-L-lysinderivate und Verfahren für die Herstellung von Lysinopril mit Hilfe dieser Verbindung.